Advanced Glycation End Products in Polycystic Ovarian Syndrome

  • E. Diamanti-Kandarakis
  • C. Piperi
  • P. Nicolopoulou-Stamati
Part of the Environmental Science and Technology Library book series (ENST, volume 22)


Polycystic ovary syndrome (PCOS), a condition associated with hyperandrogenemia, hyperinsulinemia and insulin resistance, is also presented with an increased risk for atherosclerosis. Advanced glycation end products (AGE) being a diverse and heterogeneous group of compounds have been implicated in the pathogenesis of many disorders including diabetic microvascular complications, connective tissue diseases particular in rheumatoid arthritis and neurologic conditions such as Alzheimer’s disease, as well as end-stage renal failure. Interestingly, it has been shown that precooked meals, overcooked food and several contemporary beverages contain increased amounts of AGEs which appeared to be absorbed by the intestinal tract. It is possible that this environmental contribution of exogenous AGEs to the endogenous pool in the general population and in particular in patients with increased endogenous AGE levels may be involved in the pathogenesis of atherogenesis or in the acceleration of its appearance. Recently, we have demonstrated increased AGE levels in women with PCOS which may be implicated in the endothelial dysfunction and infertility underlying this disorder.

The present chapter focuses on the detrimental effects of progressive AGE accumulation in the human body with particular emphasis on the pathological crosslinking of collagen formation, as well as on the endothelial dysfunction through increased oxidative stress, vasoconstriction, and creation of a procoangulant state and induction of pro-inflammatory responses. All these effects can alter the ovarian structure, its hormonal milieu and the whole reproductive function, further contributing to the infertility underlying the pathogenesis of PCOS.


Diabetic Nephropathy Polycystic Ovary Syndrome Advance Glycation Endproducts Human Microvascular Endothelial Cell Glycation Endproducts 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abe, H., Matsubara, T., Iehara, N., Nagai, K., Takahashi, T,, Arai, H., Kita, T., and Doi, T. (2004) Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation, J. Biol. Chem. 279, 14201-14206.CrossRefGoogle Scholar
  2. Anderson, M.M., Requena, J.R., Crowley, J.R., Thorpe, S.R., and Heinecke, J.W. (1999) The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end-products at sites of inflammation, J. Clin. Invest. 104, 103-113.Google Scholar
  3. Aronson, D. (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes, J. Hypertens. 21, 3-12.CrossRefGoogle Scholar
  4. Berkowitz, G.S., Wetmur, J.G., Birman-Deych, E., Obel, J., Lapinski, R.H., Godbold, J.H., Holzman, I.R., and Wolff, M.S. (2004) In utero pesticide exposure, maternal paraoxonase activity, and head circumference, Environ. Health Perspect. 112, 388-91.CrossRefGoogle Scholar
  5. Bierhaus, A., Hofmann, M.A., Ziegler, R., and Nawroth, P.P. (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept, Cardiovasc. Res. 37, 586-600.CrossRefGoogle Scholar
  6. Brownlee, M. (1995) Advanced protein glycosylation in diabetes and aging, Ann. Rev. Med. 46, 223-234.CrossRefGoogle Scholar
  7. Bucala, R., and Cerami, A. (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging, Adv. Pharmacol. 23, 1-34.Google Scholar
  8. Burghen, G.A., Givens, J.R., and Kitabchi, A.E. (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease, J. Clin. Endocrinol. Metab. 50, 113-116.Google Scholar
  9. Cai, W., Gao, Q.D., Zhu, L., Peppa, M., He, C., and Vlassara, H. (2002) Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction, Mol. Med. 8, 337-346.Google Scholar
  10. Candido, R., Forbes, J.M., Thomas, M.C., Thallas, V., Dean, R.G., Burns, W.C., Tikellis, C., Ritchie, R.H., Twigg, S.M., Cooper, M.E., and Burrell, L.M. (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes, Circ. Res. 92, 785-792.CrossRefGoogle Scholar
  11. Chang, R.J., Nakamura, R.M., Judd, H.L., and Kaplan, S.A. (1983) Insulin resistance in nonobese patients with polycystic ovarian disease, J. Clin. Endocrinol. Metab. 57, 356-359.Google Scholar
  12. Conway, G.S., Agrawal, R., Betteridge, D.J., and Jacobs, H.S. (1992) Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome, Clin. Endocrinol. 37, 119-25.Google Scholar
  13. Diamanti-Kandarakis, E., and Dunaif, A. (1996) New perspectives in polycystic ovary syndrome, Trends Endocrinol. Metab. 7, 267-271.CrossRefGoogle Scholar
  14. Diamanti-Kandarakis, E., Piperi, C., Creatsas, G., and Kalofoutis, A. (2005) Increased levels of Advanced glycation End products in women with polycystic ovary syndrome, Clin. Endocrinol. 62, 37-43.CrossRefGoogle Scholar
  15. Diamanti-Kandarakis, E., Alexandraki K., Protogerou A., Piperi C., Papamichael, C., Aessopos, A., Lekakis, J., and Mavrikakis, M. (2005b) Metformin administration improves endothelial function in women with polycystic ovary syndrome, Eur. J. Endocrinol. 152, 749-756.CrossRefGoogle Scholar
  16. Dunaif, A., Graf, M., Mandeli, J., Laumas, V., and Dobrjansky, A. (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia, J. Clin. Endocrinol. Metab. 65, 499-507.Google Scholar
  17. Dunaif, A., Givens, J.R., Haseltine, F., and Merriam, G.R. (1992) The polycystic ovary syndrome, Cambridge: Blackwell.Google Scholar
  18. Facchiano, F., Lentini, A., Fogliano, V., Mancarella, S., Rossi, C., Facchiano, A., and Capogrossi, M.C. (2002) Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo, Am. J. Pathol. 161, 531-541.Google Scholar
  19. Faist, V., and Erbersdobler, H.F. (2001) Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction, Ann. Nutr. Metab. 45, 1-12.CrossRefGoogle Scholar
  20. Fiuza, C., Bustin, M., Talwar, S., Tropea, M., Gerstenberger, E., Shelhamer, J.H., and Suffredini, A.F. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells, Blood. 101, 2652-2660.CrossRefGoogle Scholar
  21. Foerster, A., and Henle, T. (2003) Glycation in food and metabolic transit of dietary AGEs: Studies on urinary excretion of pyrraline, Biochem. Soc. Trans. 31, 1383-1385.Google Scholar
  22. Friedman, E.A. (1999) Advanced glycation end-products in diabetic nephropathy, Nephrol. Dial. Transplant. 14, 1-9.CrossRefGoogle Scholar
  23. Furth, A.J. (1997) Glycated proteins in diabetes, Br. J. Biomed. Sci. 54, 192-200.Google Scholar
  24. John, W.G., and Lamb, E.J. (1993) The Maillard or browning reaction in diabetes, Eye 7, 230-237.Google Scholar
  25. Harlow, C.R., Rae, M., Davidson, L., Trackman, P.C., and Hillier, S.G. (2003) Lysyl oxidase gene expression and enzyme activity in the rat ovary: regulation by follicle-stimulating hormone, androgen, and transforming growth factor-beta superfamily members in vitro, Endocrinology 144, 154-162.CrossRefGoogle Scholar
  26. Hedrick, C.C., Thorpe, S.R., Fu, M.X., Harper, C.M., Yoo, J., Kim, S.M., Wong, H., and Peters, A.L. (2000) Glycation impairs high-density lipoprotein function, Diabetologia 43, 312-320.CrossRefGoogle Scholar
  27. Henle, T., Deppisch, R., and Ritz, E. (1996) The Maillard reaction: From food chemistry to uremia research, Nephrol. Dial. Transplant. 11, 1719-1722.Google Scholar
  28. Henle, T., and Miyata, T. (2003) Advanced glycation end products in uremia, Adv. Ren. Replace. Ther. 10, 321-31.CrossRefGoogle Scholar
  29. Hoff, H.F., Whitaker, T.E., and O’Neil, J. (1992) Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition, J. Biol. Chem. 267, 602-609.Google Scholar
  30. Hofmann, S.M., Dong, H.J., and Li, Z. (2002) Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse, Diabetes 51, 2082-2089.CrossRefGoogle Scholar
  31. Hsieh, H.L., Schafer, B.W., Weigle, B., and Heizmann, C.W. (2004) S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells, Biochem. Biophys. Res. Commun. 316, 949-959.CrossRefGoogle Scholar
  32. Koschinsky, T., He, C.J., and Mitsuhashi, T. (1997) Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy, PNAS. 94, 6474-6479.CrossRefGoogle Scholar
  33. Kunt, T., Forst, T., Wilhelm, A., Tritschler, H., Pfuetzner, A., Harzer, O., Engelbach, M., Zschaebitz, A., Stofft, E., and Beyer, J. (1999) Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products, Clin. Sci. 96, 75-82.CrossRefGoogle Scholar
  34. Makita, Z., Yanagisawa, K., Kuwajima, S., Bucala, R., Vlassara, H., and Koike, T. (1996) The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis, Nephrol. Dial. Transplant. 11, 31-33.Google Scholar
  35. Mamo, J.C., Szeto, L., and Steiner, G. (1990) Glycation of very low density lipoprotein from rat plasma impairs its catabolism, Diabetologia 33, 339-45.CrossRefGoogle Scholar
  36. Masaki, H., Okano, Y., and Sakurai, H. (1999) Generation of active oxygen species from advanced glycation end-products (AGEs) during ultraviolet light A (UVA) irradiation and a possible mechanism for cell damaging, Biochim. Biophys. Acta. 28, 45-56.Google Scholar
  37. McCance, D.R., Dyer, D.G., Dunn, J.A., Bailie, K.E., Thorpe, S.R., Baynes, J.W., and Lyons, T.J. (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus, J. Clin. Invest. 91, 2470-2478.Google Scholar
  38. Miyata, S., and Monnier, V. (1992) Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline, J. Clin. Invest. 89, 1102-1112.Google Scholar
  39. Miyata, T., Maeda, K., Kurokawa, K., and van Ypersele de Strihou, C. (1997) Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure, Nephrol. Dial. Transplant. 12, 255-258.CrossRefGoogle Scholar
  40. Monnier, V.M., Glomb, M., Elgawish, A, and Sell, D.R. (1996) The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution, Diabetes 45, S67-72.CrossRefGoogle Scholar
  41. Munch, G., Thome, J., Foley, P., Schinzel, R., and Riederer, P. (1997) Advanced glycation endproducts in ageing and Alzheimer’s disease, Brain. Res. Rev. 23, 134-43.CrossRefGoogle Scholar
  42. Nicholl, I.D., and Bucala, R. (1998) Advanced glycation endproducts and cigarette smoking, Cell. Mol. Biol. 44, 1025-33.Google Scholar
  43. Norman, R., Davies, M., Lord, J., and Moran, L. (2003) The role of style life modification in PCOS, Trends Endocrinol. Metab. 13, 251-257.Google Scholar
  44. O’Brien, J., and Morrissey, P.A. (1989) Nutritional and toxicological aspects of the Maillard browning reaction in foods, Crit. Rev. Food Sci. Nutr. 28, 211-248.CrossRefGoogle Scholar
  45. Paradisi, G., Steinberg, H.O., Shepard, M.K., Hook, G., and Baron, A.D. (2003) Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab. 88, 576-580.CrossRefGoogle Scholar
  46. Paul, R.G., and Bailey, A.J. (1999) The effect of advanced glycation end-product formation upon cell-matrix interactions, Int. J. Biochem. Cell. Biol. 31, 653-660.CrossRefGoogle Scholar
  47. Pugliese, G., Pricci, F., Romeo, G., Pugliese, F., Mene, P., Giannini, S., Cresci, B., Galli, G., Rotella, C.M., Vlassara, H., and Di Mario, U. (1997) Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end-products via a receptor-mediated mechanism, Diabetes 46, 1881-1887.CrossRefGoogle Scholar
  48. Pugliese, G., Pricci, F., Leto, G., Amadio, L., Iacobini, C., Romeo, G., Lenti, L., Sale, P., Gradini, R., Liu, F.T., and Di Mario, U. (2000) The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression, Diabetes 49, 1249-1257.CrossRefGoogle Scholar
  49. Schleicher, E.D., Wagner, E., and Nerlich, A.G. (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging, J. Clin. Invest. 99, 457-468.Google Scholar
  50. Schmidt, A.M., Hasu, M., Popov, D., Zhang, J.H., Chen, J., Yan, S.D., Brett, J., Cao, R., Kuwabara, K., and Costache, G. (1994) Receptor for advanced glycation end-products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins, PNAS 91, 8807-8811.CrossRefGoogle Scholar
  51. Schmidt, A.M., Hori, O., Chen, J.X., Li, J.F., Crandall, J., Zhang, J., Cao, R., Yan, S.D., Brett, J., and Stern, D. (1995) Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes, J. Clin. Invest. 96, 1395-1403.Google Scholar
  52. Schmidt, A.M., Hori, O., Cao, R., Yan, S.D., Brett, J., Wautier, J.L., Ogawa, S., Kuwabara, K., Matsumoto, M., and Stern, D. (1996) RAGE: a novel cellular receptor for advanced glycation end-products, Diabetes 45, S77-80.CrossRefGoogle Scholar
  53. Schmidt, A.M., Yan, S.D., Wautier, J.L., and Stern, D. (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis, Circ. Res. 84, 489-497.Google Scholar
  54. Schwenger, V., Zeier, M, and Henle, T. (2001) Advanced glycation end-products (AGEs) as uremic toxins, Nahrung/Food 45, 172-176.CrossRefGoogle Scholar
  55. Sell, D.R., and Monnier, V.M. (1990) End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen, J. Clin. Invest. 85, 380-384.CrossRefGoogle Scholar
  56. Sims, T.J., Rasmussen, L.M., Oxlund, H., and Bailey, A.J. (1996) The role of glycation cross-links in diabetic vascular stiffening, Diabetologia 39, 946-951.Google Scholar
  57. Singh, R., Barden, A., Mori, T., and Beilin, L. (2001) Advanced glycation end-products: a review, Diabetologia 44, 129-146.CrossRefGoogle Scholar
  58. Sobal, G., Sinzinger, H., and Menzel, E.J. (1999) Binding of long-term glycated low density lipoprotein and AGE-albumin by peripheral monocytes and endothelial cells, J. Recept. Signal. Transduct. Res. 19, 267-281.CrossRefGoogle Scholar
  59. Sobel, B.E. (1999) Insulin resistance and thrombosis: a cardiologist’s view, Am. J. Cardiol. 84, 37J-41J.CrossRefGoogle Scholar
  60. Stitt, A.W., Bucala, R., and Vlassara, H. (1997a) Atherogenesis and advanced glycation: promotion, progression, and prevention, Ann. N. Y. Acad. Sci. 811, 115-127CrossRefGoogle Scholar
  61. Stitt, A.W., He, C., Friedman, S., Scher, L., Rossi, P., Ong, L., Founds, H., Li, Y.M., Bucala, R., and Vlassara, H. (1997b) Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs, Mol. Med. 3, 617-627.Google Scholar
  62. Stitt, A.W., He, C., Friedman, S., Scher, L., Rossi, P., Ong, L., Founds, H., Li, Y.M., Bucala, R., and Vlassara, H. (1997c) Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs, Mol. Med. 3, 617-627.Google Scholar
  63. Stitt, A.W., He, C., and Vlassara, H. (1999) Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells, Biochem. Biophys. Res. Commun. 256, 549-556.CrossRefGoogle Scholar
  64. Takahashi, M., Kushida, K., Ohishi, T., Kawana, K., Hoshino, H., Uchiyama, A., and Inoue, T. (1994) Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders, Arthritis. Rheum. 37, 724-728.CrossRefGoogle Scholar
  65. Tanaka, N., Yonekura, H., Yamagishi, S., Fujimori, H., Yamamoto, Y., and Yamamoto, H. (2000) The receptor for advanced glycation end-products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells, J. Biol. Chem. 275, 25781-25790.CrossRefGoogle Scholar
  66. Thornalley, P.J. (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs, Cell. Mol. Biol. 44, 1013-1023.Google Scholar
  67. Thornalley, P.J. (2005) Glycation free adduct accumulation in renal disease: the new AGE, Pediatr. Nephrol. [Epub ahead of print: MH7VQE2JQJFT/Contributions/H/7/5/7/H75716140206060W_html/fulltext.html]Google Scholar
  68. Tsuchida, K., Makita, Z., Yamagishi, S., Atsumi, T., Miyoshi, H., Obara, S., Ishida, M., Ishikawa, S., Yasumura, K., and Koike, T. (1999) Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end-product inhibitor, OPB-9195, Diabetologia 42, 579-588.CrossRefGoogle Scholar
  69. Tsuji, H., Iehara, N., Masegi, T., Imura, M., Ohkawa, J., Arai, H., Ishii, K., Kita, T., and Doi, T. (1998) Ribozyme targeting of receptor for advanced glycation end-products in mouse mesangial cells, Biochem. Biophys. Res. Commun. 245, 583-588.CrossRefGoogle Scholar
  70. Uribarri, J., Peppa, M., and Cai, W. (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients, J. Am. Soc. Nephrol. 14, 728-731.CrossRefGoogle Scholar
  71. Verzijl, N., DeGroot, J., Ben, Z.C., Brau-Benjamin, O., Maroudas, A., Bank, R.A., Mizrahi, J., Schalkwijk, C.G., Thorpe, S.R., Baynes, J.W., Bijlsma, J,W., Lafeber, F.P., and TeKoppele, J.M. (2002) Crosslinking by advanced glycation end-products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis, Arthritis Rheum. 46, 114-123.CrossRefGoogle Scholar
  72. Vlassara, H. (2001) The AGE-receptor in the pathogenesis of diabetic complications, Diabetes. Metab. Res. Rev. 17, 436-443.CrossRefGoogle Scholar
  73. Vlassara, H., Cai, W., and Crandall, J. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy, PNAS. 99, 15596-15601.CrossRefGoogle Scholar
  74. Wild, R.A., Painter, P.C., Coulson, P.B., Carruth, K.B., and Ranney, G.B. (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab. 61, 946-951.CrossRefGoogle Scholar
  75. Wautier, J.L., Wautier, M.P., Schmidt, A.M., Anderson, G.M., Hori, O., Zoukourian, C., Capron, L., Chappey, O., Yan, S.D., and Brett, J. (1994) Advanced glycation end-products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications, PNAS. 91, 7742-7746.CrossRefGoogle Scholar
  76. Wells-Knecht, K.J., Brinkmann, E., Wells-Knecht, M.C., Litchfield, J.E., Ahmed, M.U., Reddy, S., Zyzak, D.V., Thorpe, S.R., and Baynes, J.W. (1996) New biomarkers of Maillard reaction damage to proteins, Nephrol. Dial. Transplant. 11, 41-47.Google Scholar
  77. Xu, B., Chibber, R., Ruggiero, D., Kohner, E., Ritter, J., Ferro, A., and Ruggerio, D. (2003) Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end-products, FASEB. J. 10, 1289-1291.Google Scholar
  78. Yamagishi, S., Fujimori, H., Yonekura, H., Yamamoto, Y., and Yamamoto, H. (1998) Advanced glycation end-products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells, Diabetologia 41, 1435-1441.CrossRefGoogle Scholar
  79. Yan, S.D., Schmidt, A.M., Anderson, G,M., Zhang, J., Brett, J., Zou, Y.S., Pinsky, D., and Stern, D. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end-products with their receptors/binding proteins, J. Biol. Chem. 269, 9889-9897.Google Scholar
  80. Yan, S.F., Ramasamy, R., Naka, Y., and Schmidt, A.M. (2003) Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond, Circ. Res. 93, 1159-1169.CrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • E. Diamanti-Kandarakis
    • 1
  • C. Piperi
    • 1
  • P. Nicolopoulou-Stamati
    • 1
  1. 1.Medical School, National and Kapodistrian University of AthensAthensGreece

Personalised recommendations